Investor Presentation
128
Investor presentation First six months of 2022
NAO remains committed to its strategic aspiration of
transforming 70% of US sales by 2022
The strategic aspiration is to transform 70% of sales
Strategy Framework for North America Operations
100%
80%
60%
40%
20%
0%
2015
Obesity care
New insulin launches
H1 2022: 71%
Aspiration: 70%
2022
New GLP-1 launches
VictozaⓇ
Mature insulin
Rare disease
NAO: North America Operations
New insulin launches includes: TresibaⓇ, Xultophy®, FiaspⓇ and follow-on brand insulin; New GLP-1 launches includes: OzempicⓇ and RybelsusⓇ
NAO
Maximise the
semaglutide
molecule
OZEMPIC RYBELSUS®
semaglutide injection
semaglutide tablets
ONCE-WEEKLY
wegovy
semaglutide injection 2.4 mg
Insulin (price pressure)
Manage
foundation
Rare disease (sustained growth)View entire presentation